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Abstract We evaluated the association between those
symptoms/behaviours of attention-deficit/hyperactivity
disorder (ADHD) that were present at diagnosis and out-
comes of treatment in children and adolescents in six
European countries. Physicians abstracted clinical records
from patients (6–17 years) diagnosed with ADHD between
2004 and 2007 and treated for C2 years. Physicians scored
the severity of impairment for core ADHD symptoms and
additional (non-core) ADHD symptoms/behaviours at
diagnosis and estimated treatment adherence (defined as an
estimated [80 % adherence on weekdays and [50 %
adherence on weekends). Treatment modalities included
pharmacological treatment, behavioural therapy, or both.
Pharmacological treatment was further subclassified by
medication class. The outcome, optimal treatment success
(OTS), was defined as complete symptom control with high
satisfaction with treatment. Multivariate logistic regression
modelling examined the relationship between OTS and
symptom impairment. Of 730 patients, 200 (27 %)
achieved OTS. These patients were more likely to dem-
onstrate lower impairment in non-core ADHD symptoms/
behaviours and have fewer pre-existing comorbidities.
They were also more likely to be adherent and engaged
with treatment, with an explicit treatment goal to improve
inattention/school performance. Neither core symptoms’
severity nor treatment types were associated with OTS.
OTS rates were low, with patients having less impairment
of non-core ADHD symptoms/behaviours and fewer
comorbidities more likely to achieve OTS. Potentially
modifiable factors affecting OTS were as follows: treat-
ment adherence, treatment engagement, and a treatment
goal to improve inattention/school performance. These data
suggest that there may be opportunities to optimize current
treatment use, and develop new treatment strategies to
improve core and non-core ADHD symptoms/behaviours.
Keywords ADHD  Children and adolescents 
Treatment outcomes  Treatment satisfaction  Symptom
impairment  Comorbidities
Introduction
Attention-deficit/hyperactivity disorder (ADHD) is a
neuro-developmental disorder with an estimated preva-
lence of 5–7 % in school-aged children worldwide (Pola-
nczyk et al. 2007; Willcutt 2012), which is consistent with
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individual European studies (Faraone et al. 2003; Ford
et al. 2003; Lecendreux et al. 2011). There is a limited
understanding of the multifactorial aetiology of ADHD
(Banaschewski et al. 2010; Curatolo et al. 2010; Pliszka
2007), and this is reflected in differences in diagnostic
criteria (Diagnostic and Statistical Manual of Mental Dis-
orders [DSM] [Fourth Edition] versus International Sta-
tistical Classification of Diseases [10th Revision]) and US
and European management guidelines, which have been
refined over time (Martenyi et al. 2009; Seixas et al. 2012;
Subcommittee on ADHD 2011). ADHD commonly affects
school-aged children and often persists into adulthood
(Banaschewski et al. 2010; Biederman and Faraone 2005).
Core symptoms include inattention, hyperactivity, and
impulsivity at levels that are significantly higher than
expected in a child of that age and developmental level.
However, ADHD is a heterogeneous disorder and patient
presentations are wide-ranging and often complex; they
frequently include the presence of additional symptoms/
behaviours such as problems interacting or communicating
with peers, conduct behaviours, and emotional symptoms
(Becker et al. 2011), or comorbid diagnoses such as autism
spectrum disorder, Tourette syndrome, depression, sleep
disorder, anxiety, aggression, oppositional defiant disorder
(ODD), bipolar disorder, schizophrenia, or drug abuse
(Biederman et al. 1998; Rommelse et al. 2009; Spencer
et al. 1999). ADHD is associated with at least one other
DSM diagnosis in a vast majority of cases, affecting as
many as two in three of all individuals with ADHD in the
general population (Gillberg et al. 2004; Hodgkins et al.
2013; Pliszka 2007; Taurines et al. 2010).
Treatment adherence and engagement of the patient and
family are positive predictors of treatment outcomes
(Charach et al. 2004; Corkum et al. 1999; Gau et al. 2006;
Hodgkins et al. 2011; Kaiser et al. 2008; MTA Cooperative
Group 1999; Pappadopulos et al. 2009; Pierce 2011; San-
chez et al. 2005; Swanson 2003). However, several studies
have suggested that the presence of additional symptoms/
behaviours and/or comorbidities is associated with poorer
outcomes (Becker et al. 2011; Danckaerts et al. 2010).
Becker et al. (2011) found no association between core
impairment levels and outcome success, and a significant
association between non-core ADHD impairment levels
and comorbidity with lower treatment success in children
and adolescents with ADHD in standard practices in Ger-
many. Despite the adverse impact of additional symptoms
and comorbidities on treatment outcomes, the medical lit-
erature to date has provided little guidance regarding
expectations and strategies for improving treatment out-
comes in these more complex cases.
We conducted a retrospective cohort study that builds on
a previous descriptive analysis of ADHD patient charac-
teristics and treatment patterns in children and adolescents
in six countries in the European Union (Hodgkins et al.
2013), and a sub-analysis of those who were treatment
adherent (Setyawan et al. 2013). The purpose of the current
study was to explore the association between the severity
of ADHD symptoms/behaviours and achievement of opti-
mal treatment success (OTS), which was defined as a
combination of complete symptom control and high satis-




This study was conducted as part of a retrospective chart
abstraction of patient medical records by their treating
physicians. Complete details regarding the study method-
ology can be obtained from Hodgkins et al. (2013). In brief,
study participants were physicians who regularly treated
patients with ADHD in France, Germany, Italy, the Neth-
erlands, Spain, and the UK. Participating physicians iden-
tified up to five of their most recent patients who met the
following criteria: (a) received a diagnosis of ADHD
between January 2004 and June 2007; (b) were followed
for at least 2 years after being diagnosed; (c) received
either pharmacological treatment or behavioural therapy
(BT) or both following the diagnosis; and (d) were not
enrolled in a clinical trial during the study period. Data
regarding both physician and patient characteristics were
collected at the time of chart abstraction. Physicians were
nominally compensated for their time.
Outcome variable
The binary outcome variable for this study, OTS, was
created using a combination of the physician’s assessment
of the patient’s ADHD symptom control (completely,
moderately, poorly, or not controlled) and their satisfaction
level with treatment (very satisfied, moderately satisfied,
neither satisfied nor dissatisfied, moderately dissatisfied,
and very dissatisfied). Descriptive results from physician
scoring of satisfaction with treatment demonstrated that
physicians were moderately or very dissatisfied with
treatment in only 3 % of patients. Given the small numbers
of patients in these groups, these levels of satisfaction were
combined with the ‘moderately satisfied’ and ‘neither sat-
isfied nor dissatisfied’ responses (55 %) and compared to
the ‘very satisfied’ level. Similarly, physicians reported
that symptoms were not controlled in less than 0.5 % of
patients and poorly controlled in 7 %, and therefore, these
levels were combined with the ‘moderately controlled’
responses (62 %) and compared to the ‘complete control’
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group. More details and analysis supporting the OTS def-
inition were provided in a prior publication from this study
(Setyawan et al. 2013).
Explanatory variables
The principal explanatory variables were 12 ADHD symp-
toms/behaviours documented at the time of diagnosis. These
included the three ‘core’ ADHD symptoms (i.e. inattention,
hyperactivity, and impulsivity) (Hazell et al. 2011; Zhang
et al. 2005) and additional ‘non-core’ ADHD symptoms/
behaviours (categorized as anger, irritability, active defiance
of reasonable requests or rules [i.e. active defiance], tendency
to blame other people, challenges with school performance,
social problems when interacting with family/teachers/peers/
colleagues [i.e. social interaction problems], difficulty mak-
ing the right choices, inappropriate behaviour, and ‘other’
symptoms/behaviours). These additional symptoms/behav-
iours are well known to clinicians treating ADHD, as similar
items are included in assessment tools often used among the
school-aged ADHD population (Goodman 1997; Swanson
1992). These additional ADHD symptoms/behaviours will be
referred to as ‘non-core symptoms’. Physicians reported the
presence or absence of each symptom/behaviour at diagnosis
and then scored each of the core and non-core symptoms
with respect to ADHD impairment using a scale from 1 to
10, with 1 being the lowest impairment and 10 being the
highest impairment. Aggregated impairment scores at diag-
nosis were also examined for all symptoms and separately for
core and non-core symptom categories.
Other clinical characteristics used as explanatory vari-
ables included: ADHD in the family (i.e. parent, sibling, or
not known), comorbid diagnoses (categorized as depres-
sion, anxiety, aggression, ODD, obsessive compulsive
disorder [OCD], insomnia/sleep disturbances, behavioural
disorder, learning disability/difficulty, Tourette syndrome/
tic disorder, epilepsy, bipolar disorder, schizophrenia, drug
abuse, alcohol abuse, and autism spectrum disorder), and
the total number of comorbid conditions present at
diagnosis.
The study definition of initiating a new ‘therapy’ was
either the addition or discontinuation of an ADHD medi-
cation or BT. For each patient, the most recent five thera-
pies were abstracted. For this study, the analysis was based
on the ‘current’ therapy (i.e. that which was currently being
taken by the patient at the time of chart abstraction).
Treatment was categorized based on two different rules:
treatment modality and treatment type. Treatment modality
included pharmacological therapy only, BT only, or both.
In this study, there was no differentiation of type of BT
(child, parent, and family). Treatment type included all
three modalities and was further refined by subclassifying
the pharmacological treatment group by medication
classes: long-acting (LA) methylphenidate (MPH), short-
acting (SA) MPH, SA amphetamine, atomoxetine, other
pharmacotherapy, and multiple pharmacotherapies. Addi-
tional explanatory variables related to treatment included
the number of therapies recorded on the patient’s chart (up
to the most recent five), the number of years of follow-up
since diagnosis, the number of therapies per follow-up
year, and concomitant psychotropic medications.
The following pre-specified treatment goals were also
reviewed and analysed: improve concentration/functioning
at school/work (i.e. improve inattention), control hyper-
activity, control aggression, control impulsivity, increase
self-esteem, reduce chances of substance abuse, enable
patient to build relationships, enable patient to maintain
relationships, improve behaviour, reduce likelihood of
being in trouble, reduce disruption at home, enable par-
ticipation in activities outside of school, minimize chance
of exclusion from school/work, improve family relation-
ship, and other. Multiple answers were allowed per patient.
Goals were grouped based on clinical considerations and
empirical evidence (i.e. factor analysis) to reduce the
number of categories. As treatment goals represent
expectations from treatment and may be associated with
physician-reported satisfaction with treatment and symp-
tom control, the grouped goals were included as potential
predictors.
Patient engagement with treatment and family involve-
ment with treatment were measured independently and
continuously on a scale from 1 to 10, with 1 being ‘no
engagement/involvement’ and 10 being ‘strong engage-
ment/involvement’.
A patient was considered adherent to pharmacotherapy
when the physician reported that he or she was believed to
be taking the medication at least 80 % of the time on
weekdays and 50 % on weekends and holidays. Adherence
was also defined for BT (i.e. 80 % of scheduled sessions),
and if BT did not take place on weekends or holidays, then
only the weekday value was used for classification.
Statistical analyses
Descriptive statistics were reported for the study popula-
tion, and the identification of predominant ADHD symp-
toms/behaviours at diagnosis and mean impairment scores
were compared by OTS. Descriptive statistics included: the
frequency (n), the percentage (%), the mean, standard
deviation (SD), median, and interquartile range. Deviations
from expected rates in categorical variables were tested
with one degree of freedom chi-square tests. Covariates
were tested individually to assess the significance of their
association with OTS (bivariate two-sample t tests and chi-
square tests for continuous and categorical covariates,
respectively).
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Multiple logistic regression was used to examine the
relationship between OTS and the level of symptom/behav-
iour impairment, adjusted for other covariates that were sig-
nificantly associated with OTS in bivariate tests. Covariates
significantly associated with the outcome (p \ 0.05) were
included in a stepwise multiple logistic regression (p \ 0.05
for entry and retention) to select a subset of simultaneously
significant covariates that were associated with OTS. Odds
ratios (ORs) with 95 % confidence intervals (CIs) were
reported for the final selected model.
Finally, after the significant main effects were selected
with the stepwise procedure, second-order terms (interac-
tions and squared continuous covariates) were tested for
the selected model, and those significant over and above
the main effects were retained. The Hosmer–Lemeshow
goodness-of-fit test was used to assess the adequacy of the
model, and the c-statistic was used to evaluate the accuracy
of prediction. The c-statistic ranges from 0.5 to 1, where
c = 1 for a perfect model and c = 0.5 for a model no
better than random classification (Hosmer and Lemeshow
1989). To illustrate the relationships explained by the final
model, curves describing the estimated probability of OTS
were calculated for several combinations of covariates.
To provide further interpretability for the model ORs,
multiple logistic regression modelling was repeated using
categorical variables for continuous predictors of OTS. The
aggregate non-core symptom impairment variable was
replaced with the categorical variable ‘3 or more non-core
symptoms (Y/N)’, and the level of patient engagement was
replaced with dummy variables indicating the third and
fourth quartiles of the patient engagement score (using the
lower 50 % of engagement scores as a reference).
All reported tests were two-sided at a significance level
of a = 0.05 significance level. Data were analysed using
SAS statistical software (version 9.2, SAS Institute, Inc.,
Cary, NC, USA). This study complied with all US and
International Conference on Harmonization human sub-
jects ethics committee requirements and was approved by
the Research Triangle Institute institutional review board.
Results
Data were collected by 340 physicians from 779 eligible
patients. Of these 779 patients, 730 were receiving ADHD
medication and/or BT at the time of the chart review and
were included in this analysis. This final study population
had a mean (SD) age of 12.0 (2.6) years and 82 % were
aged 10–17 years (range 6–17 years); the majority were
male (77 %). Almost one-third (28 %) had an immediate
family member diagnosed with ADHD. The distribution of
patients (physicians) by country was as follows: France 118
(50), Germany 137 (52), Italy 134 (73), the Netherlands 72
(55), Spain 132 (50), and the UK 137 (57). Overall, 48.5 %
of patients were treated by psychiatrists (France 88.5 %,
Germany 36.4 %, Italy 9.7 %, the Netherlands 50.0 %,
Spain 66.2 %, and the UK 56.8 %).
Of all patients, 30 % had two core ADHD symptoms
and 44 % had all three core ADHD symptoms of inatten-
tion, hyperactivity, and impulsivity. For non-core symp-
toms, fewer than 5 % had none and 64 % had three or
more. Forty-three per cent had all three core symptoms
plus between five and eight of the non-core symptoms,
suggesting severe difficulties. The mean (SD) total
impairment score for all twelve symptom/behaviour
impairment scores combined was 6.5 (1.5), whereas the
mean (SD) impairment scores for the three core symptoms
and for the nine additional non-core symptoms were 7.3
(1.6) and 6.2 (1.7), respectively.
Characteristics of the study population by OTS are
described in Table 1. Overall, physicians reported OTS in
27 % (200/730) of patients. Among patients achieving
OTS, 56 % had three or more additional non-core symp-
toms compared with 66 % among those not achieving OTS
(p = 0.009) (Table 1). There was no significant difference
in the mean core symptoms impairment score between
those who did and did not achieve OTS (7.2 vs 7.4,
p = 0.190), but those who achieved OTS had a signifi-
cantly lower mean impairment score for the non-core
symptoms (5.7 vs 6.4, p \ 0.0001).
Individuals who achieved OTS were perceived to have
higher average patient engagement (7.5 vs 5.9, p \ 0.0001)
and family involvement levels (8.5 vs 7.5, p \ 0.0001). Of the
patients who achieved OTS, 57.0 % had restraint of inap-
propriate behaviour as a treatment goal (factor) compared
with 67.9 % of those who did not achieve OTS (p = 0.0070).
The restraint of inappropriate behaviour as a treatment goal
factor included the following individual treatment goals:
control aggression, reduce chances of substance abuse, reduce
likelihood of being in trouble, and minimize chance of
exclusion from school/work. A similar pattern was observed
for control of hyperactivity as a treatment goal (p = 0.0443),
whereas the pattern was reversed for improving attention as a
treatment goal—of those who achieved OTS, 90 % had
improving inattention as a treatment goal compared with
74 % of patients who did not achieve OTS (p \ 0.0001).
Physicians reported that 71 % of the patients were
considered to be adherent to the ADHD treatment, with
patients achieving OTS more likely to be adherent (85 vs
66 %, p \ 0.0001), or conversely stated, adherent patients
were more likely to achieve OTS (33.7 % adherent and
14.3 % non-adherent). Fifty-three per cent of the patients
received the same treatment type over the entire study
duration for a mean (SD) of 2.5 (1.2) years, and there was
no difference in the number of therapies by OTS group. At
the time of data abstraction, most patients (66 %; 483/730)
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were receiving MPH; few (1 %; 9/730) were receiving
amphetamines (data not shown).
There were significant differences in OTS rates by
country (Fig. 1), with higher than average rates of 53 % (38/
72) in the Netherlands (p \ 0.0001) and 42 % (57/137) in
Germany (p = 0.002) and a lower than average rate of 12 %
(16/134) in Italy (p \ 0.001). Other notable differences
across countries included: (1) The Diagnostic and Statistical
Manual of Mental Disorders 4th edition diagnostic approach
was most commonly used in the Netherlands (81.1 %) and
Spain (79.1 %), while the International Classification of
Diseases 10th Revision was most common in Germany
(87.4 %); (2) the UK had the highest rate of treatment with
pharmacotherapy alone (63.7 %), while treatment with BT
alone was most common in Italy (41.0 %). Over 54 % of
patients in Italy used SA MPHs, while Spain did not report
any use. Atomoxetine was most commonly used in Italy
(36.7 %), but it was not available in France. SA ampheta-
mines were not used in France or Spain, were used by less
than 2 % of patients in Germany, the UK, and the Nether-
lands, and were most common in Italy (9.0 %); and (3)
adherence to ADHD treatment ranged from 50.8 % in Italy
to 80.3 % in France.
The rate of OTS was lowest for patients receiving BT
only (12 %; 11/90), and this group was the only group with
a significant deviation from the overall expected 27 % OTS








Three or more non-core symptoms, n (%) 112 (56.0) 352 (66.4) 0.009
ADHD symptomatic average impairment level—all symptoms <0.0001
Mean (SD) 6.10 (1.61) 6.66 (1.41)
Median (range) 6.1 (2.5–10.0) 6.8 (1.8–10.0)
ADHD symptomatic average impairment level—core symptoms 0.190
Mean (SD) 7.21 (1.71) 7.39 (1.49)
Median (range) 7.3 (2.0–10.0) 7.7 (3.0–10.0)
ADHD symptomatic average impairment level—non-core symptoms <0.0001
Mean (SD) 5.68 (1.79) 6.39 (1.56)
Median (range) 5.8 (1.6–10.0) 6.6 (1.0–10.0)
Number of pre-existing comorbidities <0.0001
Mean (SD) 2.09 (1.85) 3.00 (2.11)
Median (range) 2.0 (0.0–7.0) 3.0 (0.0–9.0)
Male sex, n (%) 145 (73.5) 420 (79.3) 0.059
Patient engagementc
Mean (SD) 7.45 (1.59) 5.92 (2.09)
Median (range) 8.0 (2.0–10.0) 6.0 (1.0–10.0) <0.0001
Family involvementd
Mean (SD) 8.46 (1.29) 7.51 (1.79) <0.0001
Median (range) 9.0 (3.0–10.0) 8.0 (1.0–10.0)
Treatment goals (multiple per patient), n (%)
Restrain inappropriate behaviour (factor) 114 (57.0) 360 (67.9) 0.0070
Control hyperactivity 158 (79.0) 452 (85.3) 0.0443
Improve inattention 179 (89.5) 390 (73.6) <0.0001
Treatment adherente 170 (85.4) 335 (65.8) <0.0001
ADHD attention-deficit/hyperactivity disorder, SD standard deviation
a Percentage for categorical variables and mean (SD) for continuous variables
b Significant chi-square p values (p \ 0.05) in bold
c Physician-rated extent of patient engagement in ADHD condition and treatment (1 = no engagement and 10 = strong engagement)
d Physician-rated involvement of family/caregiver in patient’s ADHD condition and treatment (1 = no involvement and 10 = strong
involvement)
e 22/730 patients were missing adherence data. Adherence was defined as taking the treatment for at least 80 % of the time on weekdays and
50 % on weekends and holidays
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rate (p = 0.006). There was no significant difference in
OTS rate for the remaining current treatment type cate-
gories (all included medications), ranging from 26 % (70/
268) for the combination of pharmacotherapy ? BT to
34 % (72/214) for LA MPH.
Figure 2 shows the percentage of patients with impair-
ment at diagnosis across all symptoms/behaviours for those
who did and did not achieve OTS. Non-OTS patients had
significantly higher rates of anger (p = 0.002) and defiance
(p = 0.009). Non-significant relationships were observed
for all the other symptoms/behaviours, with the exception
of challenges with school performance, which was signif-
icantly negatively associated with OTS (p = 0.022).
Patients who did and did not achieve OTS presented with
an average of 3.1 versus 3.5 non-core symptoms
(p = 0.026), respectively.
Figure 3 shows the mean symptom/behaviour impairment
scores for those who did and did not achieve OTS. For non-
OTS patients, a significantly higher mean impairment score
was observed for the individual symptoms of impulsivity
(p = 0.005), anger (p \ 0.0001), irritability (p \ 0.001),
defiance (p \ 0.0001), tendency to blame other people
(p = 0.001), social interaction problems (p \ 0.0001), dif-
ficulty making the right choices (p = 0.025), and inappro-
priate behaviour (p \ 0.0001). Inattention was the only
symptom for which the impairment score was significantly
higher in those with OTS (p = 0.018).
Most of the patients (77 %) had at least one psychiatric
or developmental comorbidity. Figure 4 describes the
proportion of patients with each of the documented
comorbidities by OTS group. The mean number of pre-
existing comorbidities was significantly lower in the
patients who experienced OTS (2.1 vs 3.0, p \ 0.0001).
Non-OTS patients were more likely to present with autism
spectrum disorder (p = 0.015), aggression (p \ 0.0001),
OCD (p = 0.029), insomnia/sleep disturbances
(p = 0.001), behavioural disorder (p = 0.005), Tourette
syndrome/tic disorder (p \ 0.001), learning disabilities
(p \ 0.001), and epilepsy (p = 0.033) compared with
patients who achieved OTS.
The final multivariate logistic regression model is
described in Table 2. For this model, the impairment scores
for non-core symptoms were aggregated into a single
variable. This variable did not include challenges with
school performance or other symptoms, as these individual
symptoms/behaviours were not statistically associated with
OTS. A lower non-core symptom impairment score was
highly associated with OTS. Patients who had a lower non-
core symptom impairment level (i.e. 1 SD or 1.8 points
























































































































Fig. 1 Characteristics associated with optimal treatment success.
a Germany (p = 0.002) and the Netherlands (p \ 0.0001) had a
significantly higher OTS rate and Italy (p \ 0.001) a significantly
lower OTS rate compared to the overall OTS rate. b n = 668 due to
missing values. c ‘BT only’ was the only treatment type with a
significantly different OTS rate compared to the overall OTS rate
(p = 0.006). BT behavioural therapy, LA long acting, MPH methyl-
phenidate, Rx pharmacotherapy, SA short acting. ‘Other Rx’ included
medications other than MPH, amphetamine, and atomoxetine; ‘No. of
therapies’ denotes number of therapies (as per study definition)
recorded on the patient’s chart
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from the model was 0.762, and the reversed OR for the
reverse interpretation of the predictor was 1/0.762).
Covariates that significantly contributed to the model for
OTS were as follows: treatment adherence (OR 2.0), fewer
comorbidities [specifically no pre-existing autism spectrum
disorder (reversed OR 4.4) and no Tourette syndrome/tic
disorder (reversed OR 4.4)], higher patient engagement
[OR 3.4 for 1 SD (i.e. 2.1 points higher) for a reference
patient in Germany], the treatment goal to improve atten-
tion/school performance (OR 1.8), the country of resi-
dence, and an interaction term between patient engagement
and country. The Netherlands had a significantly higher
OTS rate compared with Germany, and the UK and France
had a significantly lower OTS rate (results reported for a
median patient engagement level of 7). The adjusted effect
of treatment type was not statistically significant.
The c-statistic for the logistic regression model was
0.80, indicating that the model correctly classified OTS for
about 80 % of patients. The Hosmer–Lemeshow p value
was 0.496, demonstrating a good fit of the model.
Figure 5 illustrates the model outcome, OTS, by the
aggregated non-core symptom impairment score for eight
examples of hypothetical patients based on model predictor
combinations. This figure can be used to estimate the
probability of OTS by average non-core symptom impair-
ment level, given different combinations of patient
engagement levels, adherence to treatment, and the treat-
ment goal to improve attention. Patients in Germany who
did not present with autism spectrum disorder or Tourette
syndrome/tic disorder at diagnosis were used as represen-
tative fixed values for all sample-estimated probability
curves, and low and high patient engagement levels were
fixed at 5 (25th percentile) and 8 (75th percentile),
respectively.
As expected, the highest probability of OTS for each
fixed level of patient engagement was predicted to be
achieved by patients with a lower average non-core
symptom score who were adherent to treatment and had
improving inattention/school performance as a treatment















































































Optimal treatment success (n=200)
















































Fig. 2 Symptoms present at ADHD diagnosis. Patients could have multiple predominant symptoms. *p \ 0.05. ADHD attention-deficit/
hyperactivity disorder, SD standard deviation
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achieving OTS were those who, at each fixed level of
patient engagement, demonstrated a higher average
impairment score for non-core ADHD symptoms, were
not adherent to treatment, and did not have ‘improving
inattention/school performance’ as a treatment goal at
diagnosis. As indicated by the relative magnitude of the
estimated ORs, patient engagement had the highest effect
size among the predictors allowed to vary in Fig. 5, fol-
lowed by adherence, treatment goal to improve inattention/
school performance, and average non-core symptom
impairment level. For example, an adherent patient with an
engagement score of 8, an average non-core symptom
impairment score of 2, and without improvement in inat-
tention/school performance as a treatment goal is predicted
to have a 58.3 % (95 % CI, 38.9, 75.4 %) estimated
probability of OTS versus 50.8 % (95 % CI, 34.1, 67.4 %)
and 43.3 % (95 % CI, 28.3, 59.8 %) for similar patients
with average impairment scores for non-core symptoms of
4 and 6, respectively.
For improved interpretability, a separate logistic
regression model was developed that replaced continuous
covariates of non-core symptom impairment and level of
patient engagement with the categorical variables as
defined in the Methods section. The OR for the categorical
predictor ‘less than 3 non-core symptoms’ was 1.61 (95 %
CI, 1.10, 2.35), indicating that patients with two or fewer
non-core symptoms were 61 % more likely to achieve OTS
than patients with three or more (maximum seven) non-
core symptoms. For patients with an engagement score in
the third or fourth quartiles, the engagement ORs relative
to patients in the first and second engagement score quar-
tiles were 2.16 (95 % CI, 1.29, 3.60) and 4.46 (95 % CI,
2.86, 6.95), respectively. Estimated ORs for the other
covariates changed only slightly (data not shown).
Discussion
This study used physician-reported data to analyse the
association between ADHD symptom impairment at diag-
nosis and treatment outcomes to gain a perspective on the
relative effect of symptom impairment, comorbid psychi-
atric conditions, and other patient factors on OTS in a


















































































Optimal treatment success (n=200)
































Fig. 3 Mean (SD) impairment score at ADHD diagnosis. *p \ 0.05. ADHD attention-deficit/hyperactivity disorder, SD standard deviation
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that the physician’s assessment of treatment success was
associated with both the presence and the level of impair-
ment of non-core ADHD symptoms/behaviours at diag-
nosis and was not associated with core symptoms,
suggesting that current ADHD treatments may be most
effective for core symptoms in comparison to non-core
symptoms and comorbidities. A lower average impairment
score of these non-core symptoms was associated with a
higher likelihood of attaining OTS in our models.
In addition to the presence and severity of non-core
symptoms, several other predictors affected OTS. The
comorbidities of autism spectrum disorder or Tourette
syndrome/tic disorder were independently associated with
a decreased OTS rate.
Although data regarding treatment success for these
complex patients under routine care are scarce, our results
are consistent with other studies demonstrating that as the
severity of the disorder increases or becomes complicated
by comorbidity or psychosocial stressors, health-related
quality of life (HRQoL) impairment also worsens (Dan-
ckaerts et al. 2010; Gillberg et al. 2004). Whereas patients
and family members usually assess patient HRQoL, clini-
cians often assess patient symptom severity and functional
impairment, and these aspects have been also linked to
decreased HRQoL in patients with ADHD (Danckaerts
et al. 2010; Sawyer et al. 2002).
Although the specific type of treatment did not appear to
be associated with OTS, other potentially mutable factors
affecting OTS were identified by this study, including
adherence to treatment, patient engagement with treatment,
and the presence of a treatment goal to improve inattention/
school performance. These factors have all been hypothe-
sized and supported by previous literature. The effective-
ness of treatment, particularly pharmacotherapy, has been
well established (Pliszka 2007), and adherence to treatment
has been shown to improve outcomes not only of ADHD
symptoms (MTA Cooperative Group 1999), but also of
measures of maternal and family functionality (Gau et al.
2006). Conversely, limited patient and family adherence to
pharmacotherapy and BTs have been identified as barriers
to maximizing the effects of ADHD treatment (Charach
et al. 2004; Corkum et al. 1999; Hodgkins et al. 2011;
Kaiser et al. 2008; Pappadopulos et al. 2009; Pierce 2011;
Sanchez et al. 2005; Swanson 2003). As a core symptom,
inattention has been shown to improve with pharmaco-
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Fig. 4 Psychiatric comorbidities present at ADHD diagnosis.
*p \ 0.05. ADHD attention-deficit/hyperactivity disorder, Behavioural
Dis behavioural disturbances, Learning Dis learning disabilities,
OCD obsessive compulsive disorder, ODD oppositional defiance
disorder, SD standard deviation
Relationship between symptom impairment and treatment outcome 83
123
clear goals and strategies to reduce inattention may have
led to well-defined expectations among treating physicians
to recognize improvement in this area. Other non-core
symptoms, particularly behavioural symptoms, are less
well known to respond to pharmacological treatment, and
fewer benchmarks have been defined to measure
improvement in these other symptoms (Gillberg et al.
2004; Kaiser et al. 2008).
Treatment options in some parts of Europe are limited
and have varied over the time of the study, given that
patients primarily have access to BT, MPH, and ato-
moxetine, individually or in combination. In this study,
there were no significant differences in OTS rates among
treatment types, perhaps due to the limited pharmacologi-
cal options available. On the other hand, adherence to (any)
treatment doubled the patient’s odds of achieving OTS.
Given the unsatisfactory rate of OTS in the overall popu-
lation (27 %), improved outcomes may be achievable by
optimizing the conditions shown to affect success. Physi-
cians and patients/caregivers should consider engaging in
dialogue to ensure treatment goals are being met. In par-
ticular, efforts should be made to engage patients and their
families as much as possible in their treatment (as
engagement is a strong predictor of OTS) and to improve
treatment adherence. Where treatment goals are not
achieved, alternative treatment options may be considered.
Additionally, the development of new pharmacological
therapy and BT strategies for the improvement of core and
non-core symptoms, particularly for use in patients with
complex comorbidities, appears warranted.
Further research is needed to investigate observed
variations in the rates of OTS by country. The availability
of different medications and resources such as family and
community support or supportive educational settings,
differences in physician training and practice setting across
countries, possible differences in physician perception of
control, treatment priorities, national standards, insurance
affordability, and cultural atmosphere all vary by country
(Curatolo et al. 2010; Martenyi et al. 2009; Schlander et al.
2007; Seixas et al. 2012). This study was not designed to
address the reasons for these differences.
There are several limitations to this study that deserve
mention. Although this was a large observational study
relative to other published studies in the field, the gener-
alizability of these results at the population or country
levels remains limited because of its reliance on a conve-
nience sample. However, although absolute rates of OTS
and predictor values may have been limited by the nature
of the study sample, the results obtained from ORs (gen-
erated by logistic regression modelling) should be mini-
mally affected as OR estimates are independent of the
sampling design.
The OTS outcome measure was a new composite mea-
sure developed for this study and was derived from mea-
sures of physician-reported symptom control and
satisfaction with treatment. Satisfaction measures are often
skewed towards higher levels of satisfaction and frequently
require categorization of results to achieve interpretability
(Williams et al. 1998). Simplification of the analysis by
focusing on the patients with the best outcomes likely
underestimated the rate of treatment success. However,
given that the goal of ADHD management is to strive for
optimal, rather than intermediate, outcome and given that
moderate and poor outcome groups showed greater simi-
larity to each other in their relationship with ADHD
symptoms, our definition of OTS appeared adequately
supported by the data at hand. Furthermore, this approach
is analogous to accepted dichotomization of response
defined by the Clinical Global Impression scale into 1 or 2
Table 2 Multiple logistic regression model for predicting OTS
Covariate OR (95 % CI)
c = 0.80a
p = 0.496b
Non-core symptoms: ADHD impairment 0.762 (0.621, 0.934)
Average (1–10) [mean (SD) = 6.0 (1.8)]c
Pre-existing autism 0.229 (0.063, 0.835)
Pre-existing Tourette syndrome/tic disorder 0.229 (0.064, 0.828)
Treatment adherenced 2.025 (1.235, 3.319)
Improved attention treatment goal 1.790 (1.025, 3.125)
Patient engagemente (1–10)
[mean (SD) = 6.4 (2.1)]
3.390 (1.829, 6.285)
Country (Germany as reference)f
France 0.461 (0.248, 0.857)
Italy 0.588 (0.281, 1.229)
Netherlands 2.232 (1.129, 4.425)
Spain 0.664 (0.368, 1.198)
UK 0.399 (0.189, 0.845)
ADHD attention-deficit/hyperactivity disorder, CI confidence interval,
OR odds ratio, OTS optimal treatment success, SD standard deviation
a c-statistic of 1 indicates a perfect model, and c-statistic of 0.5
indicates the model is no better than random classification
b Hosmer–Lemeshow test
c Defined as the non-core ADHD symptom impairment average for
the individually significant symptom impairments (anger, irritability,
defiance, blame others, social interaction problems, difficulty making
right decisions, and inappropriate behaviour). This variable did not
include challenges with school performance or other symptoms, as
these individual symptoms/behaviours were not statistically associ-
ated with OTS
d Defined as [80 % adherence on weekdays and [50 % adherence
on weekends
e Interacted with country: OR (95 % CI) reported for reference
country (Germany)
f Interacted with patient engagement: OR (95 % CI) reported for
median patient engagement level of 7.0
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(response) versus 3 or greater (non-response), which also
underestimates treatment response. Similarly, having
responders defined by a threshold of 25 %, as commonly
defined in clinical papers, is also somewhat arbitrary and
underestimates treatment response.
This study relied on physician-reported data, which
may not be entirely consistent with the perception of the
patients or their carers. If these data had been collected
from various independent sources, particularly with
respect to OTS, it is possible that correlations observed in
this study may have been attenuated. The source of
information in the charts might vary, and ADHD impact
and symptom ratings can vary by informant. Data on the
informant were not collected and did not account for this
potential source of variation. Because our OTS measure
has not been psychometrically validated, there is no
estimate of the variability attributed to test–retest discor-
dance and to differences in interpretation of satisfaction
and symptom control across physicians and countries.
Additionally, the definitions and rating scales for the non-
core ADHD symptoms had not been validated prior to
their use in this investigation. In some cases, the non-core
ADHD symptoms and comorbid diagnoses used in this
study overlap. Some non-core ADHD symptoms (e.g.
active defiance or inappropriate behaviour) constitute core
symptoms for comorbid conditions (e.g. ODD or behav-
ioural disorder), and it can be argued that there is no clear
distinction between these two domains of covariates.
However, the multiple regression model presented con-
tains an optimal selection of covariates chosen from the
complete pool of covariates that represented a
comprehensive measurement of impairment and comorbid
burden. Retrospective evaluation of treatment goals and
presence and severity of symptoms by physicians may
have been biased. To try to minimize the bias, physicians
were instructed in the questionnaire to rely solely on chart
information to respond to questions rather than on
memory. The results of this study should be confirmed by
future studies using more targeted investigations that
employ defined sampling schemes, patient- and carer-
reported adherence and symptom control measures, and
comprehensive outcome measures with established valid-
ity. Ideally, studies should utilize population-based
cohorts.
Conclusion
This study provides insight regarding the impact of a wide
range of ADHD symptoms and behaviours on treatment
outcomes for children and adolescents under routine clin-
ical care as documented by their physicians. Overall,
physician-reported OTS in this European routine care set-
ting seems to be low. High impairment levels in non-core
symptoms were negatively associated with OTS, whereas
impairment levels in core ADHD symptoms were not.
Future research is necessary to confirm and further
understand this observation. Potentially mutable factors
associated with OTS included treatment adherence, patient
engagement, and specific goals of improving symptoms of
inattention/school performance. Achieving OTS is likely to
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of optimal treatment success by
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treatment, and inattention
improvement as treatment goal.
Estimated probabilities from
multiple logistic regression
model for patients from
Germany (as the reference
country) not presenting with
autism or Tourette syndrome.
High and low patient
engagement levels were defined
as 5 (25th percentile) and 8
(75th percentile), respectively.
Pt patient
Relationship between symptom impairment and treatment outcome 85
123
and this should be taken into consideration by physicians
and discussed with the patients and their families.
The variability and complexity of the presentation of
patients with ADHD that is highlighted here, coupled with
the apparently low treatment success rate, suggest that
opportunities exist for the development of improved
treatments and support for children and young people with
ADHD and their families.
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